Guardian Partners Inc. Buys 1,230 Shares of Eli Lilly and Company $LLY

Key Points

• Guardian Partners Inc. has increased its stake in Eli Lilly by 29.4%, now owning 5,417 shares valued at about $4.49 million.
• Eli Lilly reported a 37.6% increase in quarterly revenue year-over-year, reaching $15.56 billion and also surpassed earnings estimates with $6.31 EPS.
• The company has announced a quarterly dividend of $1.50, representing an annualized amount of $6.00 with a yield of 0.8%.

Guardian Partners Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,417 shares of the company's stock after buying an additional 1,230 shares during the quarter. Guardian Partners Inc.'s holdings in Eli Lilly and Company were worth $4,493,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. GAMMA Investing LLC lifted its stake in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares during the period. Wellington Management Group LLP lifted its stake in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after buying an additional 81,587 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Eli Lilly and Company by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock valued at $5,469,527,000 after buying an additional 969,376 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity

In other news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $11.35 during trading hours on Tuesday, hitting $749.99. 2,983,536 shares of the company's stock traded hands, compared to its average volume of 4,436,129. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The stock has a market capitalization of $709.84 billion, a price-to-earnings ratio of 49.02, a PEG ratio of 1.03 and a beta of 0.47. The company has a fifty day simple moving average of $743.02 and a 200-day simple moving average of $779.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm posted $3.92 EPS. The business's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.